Meeting
2021 Genitourinary Cancers Symposium
Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).
Authors
Amna Falak Sher
Stony Brook University Hospital, Stony Brook, NY
Amna Falak Sher , Justine Yang Bruce , Nashat Y. Gabrail , Ian Churchill Anderson , Anna Patrikidou , Rachel E. Sanborn , Jae Yong Cho , Arielle Shebay Lee , Jong-Seok Lee , Louise M. Nott , Do-Youn Oh , Sang Cheul Oh , Sung Yong Oh , Yinghui Wang , Zejing Wang , Troy H. Guthrie
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Advanced Prostate Cancer
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04032704
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS185)
DOI
10.1200/JCO.2021.39.6_suppl.TPS185
Abstract #
TPS185
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).
First Author: Amna Falak Sher
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel P. Petrylak
Poster
2022 ASCO Genitourinary Cancers Symposium
DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1/2 multicenter study.
First Author: Manish R. Patel
Poster
2021 ASCO Annual Meeting
A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.
First Author: Pierangela Sepe